|front |1 |2 |3 |4 |5 |6 |7
|8 |9 |10 |11 |12 |13 |14 |15 |16 |17 |18 |19 |20 |21 |22 |23 |24 |25 |26 |27 |28 |29 |30 |31 |review
*NCEP ATP III=National Cholesterol Education Program Adult Treatment Panel III.
†Some male patients can develop multiple metabolic risk factors when waist circumference is only marginally increased (e.g., 94–102 cm [37–40 inches]).
|Did you see
the Part I of this lecture?
In May 2001, the National Cholesterol Education Program (NCEP) released their third set of guidelines that standardize the clinical assessment and management of hypercholesterolemia.1
The new guidelines stress the importance of an aggressive therapeutic approach in the management of elevated LDL cholesterol as well as designating T2DM a CV risk equivalent.1
Notably, the guidelines recognize the metabolic syndrome as a secondary target of risk-reduction therapy, after the primary target of LDL cholesterol.1
The guidelines also identify the clinical factors that comprise the metabolic syndrome—abdominal obesity, increased triglycerides, decreased HDL cholesterol, increased blood pressure, and increased fasting glucose.1
1. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (ATP III). JAMA. 2001;285(19):2486-2497.